Tech Company Financing Transactions
Design Therapeutics Funding Round
On 1/28/2021, Design Therapeutics raised $125 million in Series B funding from Logos Capital, BlackRock and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
1/28/2021
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Design Therapeutics' novel GeneTAC platform, which leverages the disease modifying potential of genomic medicines with proprietary advances in transcriptional regulation chemistry, to create a pipeline of GeneTAC molecules.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6005 Hidden Valley Rd. 220
Carlsbad, CA 92011
USA
Carlsbad, CA 92011
USA
Phone
Undisclosed
Website
Email Address
Overview
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company's lead program is focused on the treatment of Friedreich's ataxia and discovery efforts are ongoing in other degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Pratik Shah
Chief Executive Officer
João Siffert
Chief Operating Officer
Sean Jeffries
Co-Founder
Aseem Ansari
Browse more venture capital transactions:
Prev: 1/28/2021: Sturish venture capital transaction
Next: 1/29/2021: Encodia venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs